Mannheimia Haemolytica Bacterial Extract-Toxoid

Verify with FDA CVM →

20 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
20
Total Reports
14
Deaths Reported
7000.0%
Death Rate

Active Ingredients

Mannheimia Haemolytica Bacterial Extract-Toxoid

Administration Routes

UnknownSubcutaneousParenteral

Species Affected

Cattle 20

Most Affected Breeds

Cattle (unknown) 9
Crossbred Bovine/Cattle 4
Mixed (Cattle) 3
Aberdeen Angus 2
Holstein-Friesian also known as Holstein 1
Red Angus 1

Most Reported Reactions

Death 12
Lameness 5
Eye disorder NOS (for photophobia see 'neurological') 4
Respiratory tract disorder NOS 4
Skin abscess 4
Claw / hoof / nail disorder NOS 4
Pneumonia 4
Bloated 3
Laboured breathing 3
Lack of efficacy - NOS 3
Laceration 3
Pink eye 2

Outcome Breakdown

Died
14 (46.7%)
Outcome Unknown
13 (43.3%)
Recovered/Normal
2 (6.7%)
Ongoing
1 (3.3%)

Data Summary

Metric Value
Total adverse event reports 20
Reports involving death 14
Case-fatality rate (reported events) 7000.0%
Distinct species in reports 1
Distinct breeds in reports 6
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Mannheimia Haemolytica Bacterial Extract-Toxoid Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 20 adverse event reports referencing Mannheimia Haemolytica Bacterial Extract-Toxoid, including 14 reports in which the animal died — a 7000.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Mannheimia Haemolytica Bacterial Extract-Toxoid. Reported administration routes include Unknown, Subcutaneous, Parenteral. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Mannheimia Haemolytica Bacterial Extract-Toxoid reports are Cattle (20 reports), with Cattle accounting for the largest share. Within those species, Cattle (unknown) (9), Crossbred Bovine/Cattle (4), Mixed (Cattle) (3) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Mannheimia Haemolytica Bacterial Extract-Toxoid are Death (12), Lameness (5), Eye disorder NOS (for photophobia see 'neurological') (4), Respiratory tract disorder NOS (4). Of the 30 reports with a coded outcome, Died is the leading category at 46.7%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Mannheimia Haemolytica Bacterial Extract-Toxoid.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial